Bindarit 选择性抑制炎症趋化因子亚家族,包括单核细胞趋化蛋白 MCP-1/CCL2, MCP-3/CCL7和MCP-2/CCL8。
Bindarit exhibits selective inhibition against monocyte chemotactic proteins MCP-1/CCL2, MCP-3/CCL7 and MCP-2/CCL8.
~50 mg/kg/day口服饲喂
动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
[1] Zoja C, et al. Kidney Int, 1998, 53(3), 726-734.
[2] Shujun Ge,et al. The CCL2 synthesis inhibitor bindarit targets cells of the neurovascular unit, and suppresses experimental autoimmune encephalomyelitis.J Neuroinflammation. 2012; 9: 171. Published online 2012 Jul 12. doi: 10.1186/1742-2094-9-171.
[3] J. L. Steiner,et al. Effects of the MCP-1 synthesis inhibitor bindarit on tumorigenesis and inflammatory markers in the C3(1)/SV40Tag mouse model of breast cancer. Published in final edited form as: Cytokine. 2014 Mar; 66(1): 60–68. Published online 2014 Jan 20. doi: 10.1016/j.cyto.2013.12.011.
分子式 C19H20N2O3 |
分子量 324.37 |
CAS号 130641-38-2 |
储存方式 ﹣20 ℃冷藏长期储存。冰袋运输 |
溶剂(常温) |
DMSO 60 mg/mL |
Water <1 mg/mL |
Ethanol 60 mg/mL |
体内溶解度
NCT01109212 | Diabetic Nephropathy | Drug: Bindarit|Drug: Placebo | Aziende Chimiche Riunite Angelini Francesco S.p.A|Mario Negri Institute for Pharmacological Research | Phase 2 | 2007-03-01 | 2016-03-29 |
NCT01269242 | Coronary Restenosis | Drug: bindarit|Drug: bindarit|Drug: placebo | Aziende Chimiche Riunite Angelini Francesco S.p.A | Phase 2 | 2009-01-01 | 2016-08-04 |
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们